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Abstract
Background: Tuberculosis is the most common cause of death among patients with HIV infection living in tuberculosis
endemic countries, but many cases are not diagnosed pre-mortem. We assessed the test characteristics of urinary
lipoarabinomannan (LAM) and predictors of mortality among HIV-associated tuberculosis suspects in Tanzania.
Methods: We prospectively enrolled hospitalized HIV-infected patients in Dar es Salaam, with $2 weeks of cough or fever,
or weight loss. Subjects gave 2 mLs of urine to test for LAM using a commercially available ELISA, $2 sputum specimens for
concentrated AFB smear and solid media culture, and 40 mLs of blood for culture.
Results: Among 212 evaluable subjects, 143 (68%) were female; mean age was 36 years; and the median CD4 count 86 cells/
mm
3. 69 subjects (33%) had culture confirmation of tuberculosis and 65 (31%) were LAM positive. For 69 cases of sputum or
blood culture-confirmed tuberculosis, LAM sensitivity was 65% and specificity 86% compared to 36% and 98% for sputum
smear. LAM test characteristics were not different in patients with bacteremia but showed higher sensitivity and lower
specificity with decreasing CD4 cell count. Two month mortality was 64 (53%) of 121 with outcomes available. In
multivariate analysis there was significant association of mortality with absence of anti-retroviral therapy (p=0.004) and a
trend toward association with a positive urine LAM (p=0.16). Among culture-negative patients mortality was 9 (75%) of 12
in LAM positive patients and 27 (38%) of 71 in LAM negative patients (p=0.02).
Conclusions: Urine LAM is more sensitive than sputum smear and has utility for the rapid diagnosis of culture-confirmed
tuberculosis in this high-risk population. Mortality data raise the possibility that urine LAM may also be a marker for culture-
negative tuberculosis.
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Introduction
In Africa, tuberculosis causes significant morbidity and
mortality, especially among people with HIV infection [1]. Early
diagnosis is a high priority for tuberculosis control and to prevent
mortality [2]. Since 1996, the World Health Organization has
promoted the DOTS strategy for tuberculosis control, one aspect
of which is case detection through sputum acid fast bacillus (AFB)
smear microscopy [3]. However, the sensitivity for diagnosing
pulmonary tuberculosis using direct, unconcentrated sputum
smear methods ranges from 40 to 60% for a combination of
three examinations [4] and is lower for those with HIV co-disease
[5]. Additionally, sputum smear cannot be used for persons who
cannot produce sputum such as children and those with
extrapulmonary disease.
Lipoarabinomannan (LAM) is a cell wall lipopolysaccharide
specific for the genus Mycobacterium [6,7]. LAM is released when M.
tuberculosis is lysed by the host immune system, filtered by the
kidneys and can be detected in the urine as potential same day
diagnostic test for tuberculosis. Test characteristics for the
diagnosis of tuberculosis have been variable [8], and one study
in patients with HIV showed an association of urinary LAM with
severe tuberculosis and high mortality [9]. Theoretical advantages
of urine LAM detection includes ease of specimen collection,
reduced chance of nosocomial transmission during collection
compared to sputum, and test performance that does not depend
on an intact immune system.
The goals of the present study were to prospectively evaluate the
diagnostic accuracy of urinary LAM antigen detection among
HIV-infected patients hospitalized with suspect tuberculosis in
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diagnosis of tuberculosis. In addition we assessed the prognostic
value of urinary LAM for survival.
Materials and Methods
Patients
Eligible patients were HIV-infected adults $18 years old
admitted to one of two participating district hospitals (A and B)
in Dar es Salaam, Tanzania, and considered tuberculosis suspects
based on cough or fever for at least two weeks or unexplained
weight loss. Patients were prospectively identified by trained
research staff attending the hospital physicians’ morning report as
part of a study in the same patients to determine the optimal blood
culture method for the diagnosis of disseminated tuberculosis [10].
Research staff explained the purpose and the conduct of the study,
and requested written informed consent in Kiswahili or in English.
Studies
Within 72 hours of enrolment, a random 2 mL sample of urine
was collected in a sterile plastic container and stored at 2–8uC
within four hours for up to 24 hours before freezing or processing.
At the time of enrollment, each subject was requested to provide
two random and one early morning sputum samples for AFB
smear microscopy and culture, and also underwent phlebotomy
for repeat (confirmatory) HIV testing, CD4+ T-lymphocyte count,
and mycobacterial blood culture. A total of 40 mLs of blood were
cultured for mycobacteria by two methods : automated MB BacT
broth and manual Isolator lysis-centrifugation agar. Blood for
culture was collected by random assignment during one
phlebotomy (40 mLs) or two phlebotomies 12–24 hours apart
(20 mLs twice) to determine the optimal approach to mycobac-
terial blood culture [10]. Other tests were done at the discretion of
the attending physician.
Follow-up
At two months after enrollment, subjects underwent follow up at
the hospital (if still inpatient), at a centrally located outpatient
clinic (if discharged), or were contacted by phone if they did not
return or were unable to travel to the outpatient clinic. If the
subject died prior to follow up or could not be contacted, efforts
were made in person or by phone to gather outcome data from
next of kin, who had been identified by the subject at the time of
enrollment. Urine LAM test results were not known to personnel
conducting follow-up investigations. Mortality was defined as the
number of confirmed deaths within two months divided by the
total number of study subjects with available 2 month follow-up.
HIV testing
Serum HIV testing was performed by trained research
personnel according to the guidelines and procedures currently
approved by the Tanzania Ministry of Health. Sera were
evaluated for HIV by 2 serial rapid HIV tests: SD Bioline
(Standard Diagnostics, Inc., Korea) and Determine (Inverness
Medical, Japan). HIV testing was performed during enrolment
into the study, and both tests were required to be positive for
eligibility.
Microbiology
Sputum specimens were examined for AFB using the Ziehl-
Neelsen method and cultured for mycobacteria on Lowenstein
Jensen slants for up to 8 weeks. Blood was cultured for
mycobacteria using both an automated broth-based system
(BacT/ALERTH MB) and a manual agar-based lysis centrifuga-
tion system (Wampole
TM ISOSTATH/ISOLATOR
TM Microbial
System) according to manufacturer’s instructions (bioMe ´rieux,
Durham NC and Inverness, Waltham MA, respectively). AFB
were considered M. tuberculosis if the AFB positive isolate had
typical colonial morphology
Urine LAM test
The urine LAM test ELISA used in this study was initially
marketed as the MTB-LAM ELISA (Chemogen Inc., South
Portland ME). Mid-study, the test name was changed and
marketed as Clearview TB ELISA (Inverness Medical Innova-
tions, Waltham MA) but methods were unchanged. Urine LAM
testing was conducted according to manufacturer instructions by a
single research laboratorian who was unaware of the results of
other diagnostic tests. A 0.5–2 ml aliquot of urine was heated at
95–100uC for 30 minutes, cooled to room temperature then
centrifuged at 10,000 rpm for 15 min. Duplicate supernatant
samples per subject were refrigerated and tested by ELISA on
batches (n=10), or were frozen at 220uC and tested by ELISA in
batches (all other samples). Duplicate sample results were
averaged, and the summary interpretation was considered positive
when the optical density (OD) at 450 nm was at least 0.1 above the
average signal of the negative control. Urine LAM test results were
not provided to treating clinicians.
Analysis
A subject with tuberculosis was defined by at least one sputum
or blood culture positive for M. tuberculosis. A subject without
tuberculosis was defined by having provided at least two sputum
specimens with associated negative cultures, and negative blood
culture (if blood was obtained for culture). Sensitivity, specificity,
and positive and negative predictive values of the urine LAM test
were calculated if there was a valid urine LAM test using SPSS
and Excel.
Statistical significance was determined in univariate analyses
using Chi-square for categorical variables and the Mann-Whitney
test for non-normally distributed variables. Risk ratios and 95%
confidence intervals were estimated using generalized linear
models assuming a binomial distribution with log-link function.
An ROC curve for different OD cutoffs of the LAM urine test was
generated using a web-based calculator [11].
Human subjects approval
Human subjects research ethical review for the study was
obtained from an Institutional Review Board of the Dartmouth
Medical School (Hanover NH USA), the National Institute for
Medical Research (Dar es Salaam, Tanzania), and the Muhimbili
University of Health and Allied Sciences Ethics Review Board.
Written informed consent was obtained from all subjects prior to
enrolment into the study. The respective institutional review
boards approved the informed consent form. Subjects did not
receive monetary incentive for participation
Results
Tuberculosis
Between May 2007 and July 2008, 278 TB suspects were
approached and requested to participate in the study, 271 patients
(97%) agreed to participate. Of the 7 who did not participate the
most common reason was concern for the volume of blood that
would be drawn. Of the 271 who agreed to participate 13 patients
were HIV negative and were excluded from the study. An
additional 46 subjects were excluded because they were too weak
to produce urine for LAM testing. Of the remaining 212 subjects,
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female, median CD4 count 86 (range 1–1016) and 68 patients
(32%) were on anti-retroviral therapy (ART) at enrollment (mean
duration of ART=324 days). One hundred twelve were from
hospital A and 100 were from hospital B; there was no significant
difference in age or sex distribution between the hospital cohorts.
Tuberculosis was diagnosed by culture in 69 of 212 study subjects
(33%).
Urine LAM
Urine LAM was positive in 65 (31%) subjects including 45/69
(65%) of patients with culture-confirmed tuberculosis and 20/143
(14%) of patients without culture-confirmed tuberculosis. The
sensitivity and specificity of a positive LAM for culture-confirmed
tuberculosis were 65% and 86% respectively (Table 1) compared
to the sensitivity and specificity of sputum smear for culture
confirmed TB that was 36% and 98% for sputum smear
respectively. LAM sensitivity was higher and specificity lower
with decreasing CD4 cell count. Sensitivity was not increased in
patients with disseminated tuberculosis as defined by a positive
blood culture. In the sample of eight specimens on which dilutions
were performed, we observed consistent results in 88% (7/8, data
not shown). LAM positive rates were 2 (20%) of 10 fresh samples
versus 63 (31%) of 202 frozen samples (p=0.69).
A Receiver Operating Characteristic (ROC) curve to illustrate
how different OD cutoffs affect sensitivity and specificity of the
urine LAM is presented in Figure 1. The area under the ROC
curve was 0.83, indicating moderate test accuracy.
Mortality
A total of 121 (57%) of 212 subjects had follow up information
available at 2 months, including 38 (55%) of the subjects with
confirmed tuberculosis and 83 (58%) of the subjects without
confirmed tuberculosis (p=0.68). The remaining subjects did not
return for follow-up and could not be reached by phone. Sixty four
(53%) of 121 subjects with follow-up data died; 38 of these deaths
occurred during the enrollment hospital admission. Univariate risk
factors for mortality are shown in Table 2 and risk ratios in
Table 3. Significant associations with mortality (p,0.05) included
CD4 count, absence of anti-retroviral therapy (ART) and positive
urine LAM test. As shown in Figure 2, among those with follow up
available, mortality was 25 (66%) of 38 subjects with a positive
urine LAM test and 33 (40%) of 83 subjects with a negative urine
LAM test (p=0.011). In multivariate analysis, there was a
significant association between mortality and absence of ART
and a trend towards association with a positive LAM (Table 4).
Among culture-negative patients mortality was 9 (75%) of 12 in
LAM positive patients and 27 (38%) of 71 in LAM negative
patients (0.016). TB treatment data was available on 6 of 20 LAM-
positive, culture-negative patients: among 3 survivors all 3 had
received treatment for TB; among 3 of 9 fatal cases with data, 2
had received treatment for TB.
Table 1. Urine LAM test characteristics for 69 cases of culture-confirmed tuberculosis among 212 tuberculosis suspects.
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Culture-confirmed tuberculosis, site
Sputum culture positive (all) 41/57 (72%) 116/132 (88%) 41/57 (72%) 116/132 (88%)
[95% CI] [58%–83%] [81%–93%] [58%–83%] [81%–93%]
Sputum culture positive (positive smear) 17/23 (74%) 105/118 (89%) 17/30 (57%) 105/111 (95%)
[95% CI] [53%–89%] [82%–94%] [39%–73%] [89%–98%]
Blood culture positive 20/31 (65%) 136/181 (75%) 20/65 (31%) 136/147 (93%)
[95% CI] [45%–80%] [68%–81%] [20%–44%] [87%–96%]
Any culture positive 45/69 (65%) 123/143 (86%) 45/65 (69%) 123/147 (84%)
[95% CI] [53%–76%] [79%–91%] [56%–80%] [76%–89%]
Culture-confirmed tuberculosis, CD4 strata
CD4,50 24/31 (77%) 31/43 (72%) 24/36 (67%) 31/38 (82%)
[95% CI] [58%–89%] [56%–84%] [49%–81%] [65%–92%]
CD4 50–200 14/21 (67%) 32/34 (94%) 14/16 (88%) 32/39 (82%)
[95% CI] [43%–85%] [79%–99%] [60%–98%] [66%–92%]
CD4.200 4/13 (31%) 43/49 (88%) 4/10 (40%) 43/62 (69%)
[95% CI] [10%–61%] [75%–95%] [14%–73%] [56%–80%]
PPV=positive predictive value; NPV=negative predictive value.
doi:10.1371/journal.pone.0032876.t001
Figure 1. ROC curve assessing optical density of LAM result as
a predictor of culture-confirmed tuberculosis in a cohort of 212
HIV-infected, hospitalized patients in Dar es Salaam, Tanzania.
The area under the curve is 0.828.
doi:10.1371/journal.pone.0032876.g001
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In a population of hospitalized subjects with advanced HIV
infection and suspect tuberculosis we found that urine LAM
testing was almost twice as sensitive as AFB smear for the rapid
diagnosis of tuberculosis. Superior sensitivity is likely due in part to
the high rate of disseminated and extra-pulmonary disease where
sputum smear and/or culture may be negative but mycobacterial
antigen may still be circulating, filtered and detectable in urine.
Specificity of LAM was lower than for AFB smear, but this can be
considered an acceptable limitation in this patient population with
a high short term mortality from tuberculosis that is often
undiagnosed or untreated [10,12].
The LAM test characteristics we identified in the present study
are consistent with those described in a systematic review of seven
studies that assessed test accuracy using only microbiologically
confirmed cases (such as ours): sensitivity was 13%–93% and
specificity 87–99% [8]. Differences in test characteristics may
relate both to different LAM testing methodologies and different
patient populations. In the systematic review pooled sensitivity
estimates from the two studies that evaluated the early prototype
version of the test were significantly higher than estimates from
studies that used either of the two commercial assays [8]. Urine
collection and processing may influence accuracy, although
analysis of sub-groups in which the urine used in the assay was
either fresh or previously frozen found no statistically significant
differences between these groups [8]. In our study, most assays
were conducted on frozen samples and we had too few results on
fresh samples for comparison.
The effect of different patient populations is most evident with
HIV where sensitivity has been found to be higher in HIV-positive
than in HIV-negative patients and higher with decreasing CD4
count, as we also observed [8,13]. This could reflect a higher
circulating burden of M. tuberculosis in advanced AIDS as suggested
by a study that showed higher sensitivity with positive blood
cultures [9]. We did not find higher sensitivity with positive blood
cultures. This could reflect different levels of mycobactermia
detected by different blood culture methods, and could be resolved
with a blood culture study comparing colony forming units (CFUs)
in positive blood cultures with LAM results.
Subjects with a positive urine LAM had significantly greater
two-month mortality in univariate analysis and a trend toward
greater mortality in multivariate analysis. Further, mortality
among culture-negative subjects was significantly higher in LAM
positive than LAM negative subjects. This is concordant with the
findings of a South African study of hospitalized patients in whom
positive LAM results were associated with greater mortality among
culture-confirmed tuberculosis cases [9]. These findings raise the
intriguing possibility that urine LAM may not only be a marker for
more severe culture-positive disease but may also be a marker for
culture-negative tuberculosis, incipient tuberculosis, extra-pulmo-
nary tuberculosis, or perhaps another unindentified opportunistic
infection. Since we did not have follow-up on all subjects, and
since rigorous statistical significance was not achieved in the
multivariate analysis with our small sample size, these findings
require confirmation in a larger study.
Our data suggest a role for LAM testing in hospitalized HIV-
infected patients with suspect tuberculosis who have a very high
short-term risk of mortality. Urine LAM detected 24 patients who
were smear negative and culture-confirmed and 4 patients who
could not produce sputum for evaluation. This supports the use of
urine LAM testing combined with AFB sputum smear microscopy
for early initiation of treatment in patients with CD4 counts ,200
as suggested by Peter et al [14]. In addition HIV-positive patients
with this profile should also be started on anti-retroviral therapy
within 8 weeks, and those with a positive LAM or CD4,50 within
2 weeks [15].
We have avoided many biases seen in studies of diagnostics [16].
The spectrum of patients is representative of the patients who will
receive the test in practice (no spectrum composition bias), the
reference standard is independent of the index test (incorporation
bias), and tests were interpreted without knowledge of other test
results (reference standard bias). We have also attempted to meet
all STARD (STAndards for the Reporting of Diagnostic accuracy
studies) recommendations in this report [17]. Yet, our study has
limitations. A significant number of screened subjects were unable
to produce urine. Culture for M. tuberculosis was performed on
agar, which is less sensitive than broth, a factor which may have
lowered the apparent sensitivity and specificity of LAM testing,
and may also explain some of the culture-negative LAM positive
cases (non-tuberculous mycobacteria would have been isolated
with our culture methods). Further, although there was no evident
systematic bias in our attempts to obtain two-month follow-up
data, we cannot exclude this possibility since we only had these
data in slightly more than half of the study population. Finally the
small sample size makes it difficult to fully separate the influence of
Table 2. Risk factors for mortality among 121 tuberculosis
suspects with follow-up data.
Characteristic Died Survived P value
n=58 n=63
Age, median 37 (22–65) 38 (18–56) 0.691
Sex, Female % 39 (67%) 42 (67%) 1.000
CD4, median 30 (2–853) 106 (1–849) 0.014
On ART*, % 8 (14%) 29 (46%) ,0.001
Any TB culture positive 22 (38%) 16 (25%) 0.099
Blood culture positive 15 (26%) 1 (2%) ,0.001
Urine LAM positive 25 (43%) 13 (21%) 0.007
*ART means the patient was on ART at enrollment.
doi:10.1371/journal.pone.0032876.t002
Table 3. Univariate analysis of mortality and risk factors
among 121 tuberculosis suspects with follow-up data.
Characteristic Died (%) Risk Ratio P value
Female 39 (48.1%)
Male 19 (47.5%) 1.01 1.000
CD4.200 8 (29.6%)
CD4#200 43 (55.1%) 1.86 0.027
On ART* 8 (21.6%)
Not on ART 50 (59.5%) 2.75 ,0.001
TB culture negative 36 (43.4%)
TB culture positive 2 (57.9%) 1.33 0.171
Blood culture negative 43 (41.0%)
Blood culture positive 15 (93.8%) 2.29 ,0.001
Negative LAM 33 (39.8%)
Positive LAM 25 (65.8%) 1.65 0.011
*On ART means at the time of enrollment.
doi:10.1371/journal.pone.0032876.t003
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culture, or CD4 and ART.
Urine LAM testing is a promising rapid diagnostic for suspect
tuberculosis among hospitalized patients with HIV infection living in a
tuberculosis-endemic country. The suggestive association of a positive
urine LAM with mortality raises the possibility that urine LAM may
have a role in the diagnosis of culture-negative tuberculosis.
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